Could a tailored IVIg dose tame a rare nerve disorder in kids?
NCT ID NCT04929236
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This phase 3 trial tests two different doses of Panzyga, an intravenous immunoglobulin therapy, in children aged 2 to 17 with CIDP, a rare nerve condition causing weakness and disability. The study aims to see which dose better controls symptoms and prevents relapses, using a disability scale to measure changes. Participants receive Panzyga infusions and are monitored for safety and effectiveness over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Panzyga, a human immunoglobulin solution given intravenously
- What this could lead to
- If successful, this trial could identify the best dose of Panzyga to control CIDP symptoms and prevent relapses in children, offering a safer, more effective treatment option.
- What could go wrong
- This is a small, early-phase study with only 30 participants, so results may not apply to all children. The treatment may cause side effects like allergic reactions or headaches.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Octapharma Research Site
RECRUITINGBirmingham, Alabama, 35233, United States
-
Octapharma Research Site
RECRUITINGOrange, California, 92868, United States
-
Octapharma Research Site
RECRUITINGLouisville, Kentucky, 40202, United States
-
Octapharma Research Site
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
-
Octapharma Research Site
RECRUITINGHouston, Texas, 77030, United States
-
Octapharma Research Site
RECRUITINGCharlottesville, Virginia, 22908, United States